[Code of Federal Regulations]
[Title 5, Volume 3]
[Revised as of January 1, 2008]
From the U.S. Government Printing Office via GPO Access
[CITE: 5CFR5502.106]

[Page 790]
 
                    TITLE 5--ADMINISTRATIVE PERSONNEL
 
          CHAPTER XLV--DEPARTMENT OF HEALTH AND HUMAN SERVICES
 
PART 5502_SUPPLEMENTAL FINANCIAL DISCLOSURE REQUIREMENTS FOR EMPLOYEES OF THE 
 
Sec. 5502.106  Supplemental disclosure of prohibited financial interests 

applicable to employees of the Food and Drug Administration.

    (a) Applicability. This section does not apply to special Government 
employees.
    (b) Definitions. For purposes of this section:
    (1) Confidential filer means an employee who meets the criteria in 5 
CFR 2634.904 and who has not been excluded from the requirement of 
filing a confidential financial disclosure report under the procedures 
in 5 CFR 2634.905.
    (2) Prohibited financial interest means a financial interest 
prohibited by Sec. 5501.104(a), including those financial interests 
that are excepted under Sec. 5501.104(b) of this chapter.
    (3) Public filer means an employee who meets the criteria in 5 CFR 
2634.202 and who has not been excluded from the requirement of filing a 
public financial disclosure report under the procedures in 5 CFR 
2634.203.
    (4) Remainder of HHS has the meaning set forth in Sec. 
5501.102(b)(2) of this chapter.
    (5) Separate agency component has the meaning set forth in Sec. 
5501.102(a) of this chapter.
    (c) Report of prohibited financial interests--(1) New entrant 
employees. A new entrant employee shall report in writing within 30 days 
after entering on duty with the FDA any prohibited financial interest 
and the value thereof held upon commencement of employment with the 
agency.
    (2) Reassigned employees. An employee of a separate agency component 
other than the FDA or of the remainder of HHS who is reassigned to a 
position at the FDA shall report in writing within 30 days of entering 
on duty with the FDA any prohibited financial interest and the value 
thereof held on the effective date of the reassignment to the agency.
    (3) Incumbent employees. An incumbent employee of the FDA who 
acquires any prohibited financial interest shall report such interest 
and the value thereof in writing within 30 days after acquiring the 
financial interest.

[70 FR 5564, Feb. 3, 2005, as amended at 70 FR 51573, Aug. 31, 2005; 70 
FR 61713, Oct. 26, 2005]